Affordable Access

Publisher Website

Targeting noncoding RNAs to treat atherosclerosis.

Authors
  • Sopić, Miron1, 2
  • Vladimirov, Sandra2
  • Munjas, Jelena2
  • Mitić, Tijana3
  • Hall, Ignacio Fernando3
  • Jusic, Amela4
  • Ruzic, Dusan5
  • Devaux, Yvan1
  • 1 Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Luxembourg, Luxembourg. , (Luxembourg)
  • 2 Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. , (Serbia)
  • 3 BHF/University Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK.
  • 4 HAYA Therapeutics SA, SuperLab Suisse - Bâtiment Serine, Lausanne, Vaud, Switzerland. , (Switzerland)
  • 5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. , (Serbia)
Type
Published Article
Journal
British Journal of Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jan 01, 2025
Volume
182
Issue
2
Pages
220–245
Identifiers
DOI: 10.1111/bph.16412
PMID: 38720437
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact. LINKED ARTICLES: This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc. © 2024 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Report this publication

Statistics

Seen <100 times